^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CXCR4 mutation

i
Other names: CXCR4, CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R, Chemokine (C-X-C motif) receptor 4
Entrez ID:
Related biomarkers:
Phase 2
University of Ulm
Not yet recruiting
Last update posted :
05/13/2024
Initiation :
09/01/2024
Primary completion :
10/01/2027
Completion :
10/01/2032
MYD88 • CXCR4
|
CXCR4 mutation
|
Venclexta (venetoclax) • Rituxan (rituximab) • cyclophosphamide • cyclophosphamide intravenous
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
05/11/2022
Initiation :
05/09/2016
Primary completion :
02/14/2020
Completion :
02/07/2022
BCL2 • CXCR4
|
CXCR4 mutation
|
Venclexta (venetoclax)
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
09/02/2020
Initiation :
04/01/2015
Primary completion :
11/01/2019
Completion :
11/01/2019
MYD88 • CXCR4
|
MYD88 L265P • CXCR4 mutation
|
Rituxan (rituximab) • Ninlaro (ixazomib)